CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy

(2018) Jacob I. Contreras et al.   ACS Chemical Biology

Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy

(2018) Sandeep Rana et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

(2017) Delphine Merino et al.   Science Translational Medicine

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

(2017) Caroline M. Robb et al.   Oncotarget

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver

(2016) Anthony Letai   CANCER CELL

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

(2016) Katelyn L. O'Neill et al.   GENES & DEVELOPMENT

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

(2015) G S Choudhary et al.   Cell Death & Disease

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics

(2015) Gaurav S. Choudhary et al.   Oncotarget

Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells

(2013) Hiroki Takahashi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting the NF- B and mTOR Pathways with a Quinoxaline Urea Analog That Inhibits IKK  for Pancreas Cancer Therapy

(2013) P. Radhakrishnan et al.   CLINICAL CANCER RESEARCH

miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death

(2013) Zhiyu Chen et al.   Molecular Cancer

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

(2013) F. Abulwerdi et al.   MOLECULAR CANCER THERAPEUTICS

Perturbing pro-survival proteins using quinoxaline derivatives: A structure–activity relationship study

(2012) Rajkumar Rajule et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition

(2012) Chander Peddaboina et al.   BMC CANCER

Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells

(2012) S. Mazumder et al.   CANCER RESEARCH

BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

(2012) G. Siemeister et al.   MOLECULAR CANCER THERAPEUTICS

2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: A structure–activity relationship study

(2011) Qianyi Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs

(2011) Vashti C. Bryant et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents

(2011) Cyrille Touzeau et al.   CLINICAL CANCER RESEARCH

Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras

(2011) J. P. Eggers et al.   CLINICAL CANCER RESEARCH

Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling

(2010) Georg Feldmann et al.   CANCER RESEARCH

Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases

(2010) Gaetano Romano et al.   CELL CYCLE

Perturbation of the Bcl-2 Network and an Induced Noxa/Bcl-xL Interaction Trigger Mitochondrial Dysfunction after DNA Damage

(2010) Hernando Lopez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Proapoptotic Function of Noxa in Human Leukemia Cells Is Regulated by the Kinase Cdk5 and by Glucose

(2010) Xazmin H. Lowman et al.   MOLECULAR CELL

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

(2009) K. F. Byth et al.   MOLECULAR CANCER THERAPEUTICS

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH